Systemic Therapy for chordoma publications
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

View only
 
 
ABCDEFGH
1
Therapeutic ClassDrug NameBrand NameTargetEvidencePatientsResultsReference
2
Targeted TherapyDasatinibSprycelPDGRF, c-KITPhase II Trial32median PFS 6.3 monthsSchuetze et al. Cancer 2016
3
Targeted TherapySorafenibNexavarmultiple RTKPhase II Trial271 PR, 73% SD (at 9 months)Bompas et al. Ann Oncol. 2015
4
Targeted TherapyLapatinibEGFRPhase II Trial1813 SDStacchiotti et al. Ann Oncol. 2013
5
Targeted TherapyImatinibGleevecPDGFRPhase II Trial501 PR, 64% SD (at 6 months)Stacchiotti et al. Journal of Clinical Oncology, 2012
6
Targeted TherapySunitinibSutentmultiple RTKPhase II Trial94 SDGeorge et al. J Clin Oncol. 2009
7
Cytotoxic TherapyRubitecanOrathecinN/APhase II Trial151 PRChugh et al. J Clin Oncol. 2005
8
9
Targeted TherapyTazemetostatEZH2Phase I Trial21 CR, 1 PRChi et al. 2017 (Abstract)
10
Therapeutic VaccineGI-6301TarmogenBrachyuryPhase I Trial10median PFS 8.3 monthsHeery et al. Cancer Immunol Res. 2015
11
Targeted Therapy + Cytotoxic TherapyImatinib mesyate + metronomic cyclophosphamideGleevec + CytoxanPDGFRPhase I Trial7median PFS 10.2 monthsAdenis et al. British Journal of Cancer, 2013
12
13
Targeted TherapyPazopanib VotrientVEGFCase Report11 SDRibeiro et al. Case Rep Oncol Med. 2018
14
Immune Checkpoint Inhibitor
NivolumabOpdivoPD1Case Report11 PRMigliorini et al. OncoImmunology 2017
15
Immune Checkpoint Inhibitor
PembrolizumabKeytrudaPD1Case Report11 PRMigliorini et al. OncoImmunology 2017
16
Therapeutic VaccineMVX-ONCO-1N/ACase Report11 PRMigliorini et al. OncoImmunology 2017
17
Targeted TherapyErlotinib + LinsitinibTarceva + LinsitinibEGFR + IGF1RCase Report11 PRAleksic et al. Frontiers in Oncology 2017
18
Targeted TherapyPazopanib + SunitinibVotrient + Sutentmultiple RTKCase Series5median PFS 8.5 monthsLipplaa et al. Clin Sarcoma Res 2016
19
Targeted TherapyErlotinibTarcevaEGFRCase Report11 PRHouessinon et al. Case Reports Oncol. 2015
20
Targeted TherapyImatinibGleevecPDGFRCase Series4634 SDHindi et al. Euro J Cancer 2015
21
Targeted TherapyImatinibGleevecPDGFRCase Series22 SDRohatgi et al. Eurasian J Med 2015
22
Targeted TherapyErlotinib + BevacizumabTarceva + AvastinEGFR, VEGFCase Series33 SDAsklund et. al. Acta Oncol. 2014 Jan
23
Cytoxoic TherapyVincristine + clophosphamide +doxorubicin + etoposide + ifosfamideCase Report11 CR (durable for 3+ years)Al-Rahawan MM et al. Pediatr Blood Cancer 2012
24
Targeted TherapyThalidomideThalomideCase Report11 PRChay et al. J Clin Oncol. 2011
25
Targeted TherapyImatinibGleevecPDGFRCase Series171 SDFerraresi et al. BMC Cancer. 2010
26
Targeted TherapyImatinib + SirolimusGleevec + RapamunePDGFR + mTORCase Series98 SDStacchiotti et al. Ann Oncol. 2009
27
Targeted TherapyCetuximab + GefitinibErbitux + IressaEGFRCase Report11 PRLinden et al. Acta Oncol. 2009
28
Targeted TherapyErlotinibTarcevaEGFRCase Report11 PRSinghal et al. Anticancer Drugs. 2009
29
Targeted TherapyCetuximab + GefitinibErbitux + IressaEGFRCase Report11 PRHof et al. Onkologie. 2006
30
Targeted Therapy + Cytotoxic TherapyThalidomide + liposomal doxorubicinThalomid + DoxilCase Report11 SDSchönegger et al. Anticancer Drugs. 2005
31
Targeted TherapyImatinibGleevecPDGFRCase Series64 symptomatic improvmentCasali et al. Cancer 2004
32
Cytotoxic TherapyIfosfamide + doxorubicinCase Report11 PRScimeca eta al. J Pediatr Hematol Oncol. 1996
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
Loading...
Main menu